University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Hyunseok Kang, MD

Hyunseok Kang, MD

Associate Professor of Clinical Medicine, UCSF

Cancer Center Program Memberships

Experimental Therapeutics

Research Summary

Dr.Hyunseok "Hyu" Kang is a medical oncologist and a clinician scientist focusing on head and neck cancers including squamous cell carcinomas of head and neck (SCCHN), salivary gland cancers, thyroid cancers and other rare cancers of head and neck. Dr.Kang joined UCSF from the Johns Hopkins University School of Medicine in Baltimore, MD where he was an Assistant Professor of Oncology, Otolaryngology - Head and Neck Surgery.

Dr.Kang completed his medical degree and public health degree at Yonsei University in Seoul, South Korea, then came to the US and had residency training at St.Luke's Roosevelt Hospital Center/Columbia University in New York City. He completed hematology and medical oncology fellowship at Emory University in Atlanta, GA.

Dr.Kang's research focus is development of clinical trials with novel therapeutic agents for patients with head and neck cancers. He has conducted/participated a number of clinical trials with immune checkpoint inhibitors and targeted therapy agents.

Education

  • Yonsei University College of Sciences, Seoul, Korea, Premed Cert, 02/1998, Premedical Sciences
  • Yonsei University College of Medicine, Seoul, Korea, M.D., 02/2002, Medicine
  • Yonsei University Graduate School of Public Health, Seoul, Korea, M.P.H., 08/2007, Epidemiology and Statistics
  • St.Luke’s-Roosevelt Hospital Center/Columbia University College of P&S, New York, NY, Postdoctoral 06/2010 Internal Medicine Residency
  • Emory University School of Medicine, Atlanta, GA, Postdoctoral. 06/2013, Hematology/Oncology Fellowship

Professional Experience

  • 2018-present
    Associate Professor, Department of Medicine, University of California, San Francisco
  • 2015-2018
    Assistant Professor, Department of Oncology, Johns Hopkins University, Baltimore, MD
  • 2013-2015
    Instructor, Department of Oncology, Johns Hopkins University, Baltimore, MD

Honors & Awards

  • 2005
    Excellence in Public Health Service, Ministry of Health and Welfare, South Korea
  • 2012
    Travel Award, AACR/ASCO Methods in Clinical Research, Vail, CO

Selected Publications

  1. Shen J, Oza AM, Del Castillo I, Duzkale H, Matsunaga T, Pandya A, Kang HP, Mar-Heyming R, Guha S, Moyer K, Lo C, Kenna M, Alexander JJ, Zhang Y, Hirsch Y, Luo M, Cao Y, Wai Choy K, Cheng YF, Avraham KB, Hu X, Garrido G, Moreno-Pelayo MA, Greinwald J, Zhang K, Zeng Y, Brownstein Z, Basel-Salmon L, Davidov B, Frydman M, Weiden T, Nagan N, Willis A, Hemphill SE, Grant AR, Siegert RK, DiStefano MT, Amr SS, Rehm HL, Abou Tayoun AN. Consensus interpretation of the p.Met34Thr and p.Val37Ile variants in GJB2 by the ClinGen Hearing Loss Expert Panel. Genet Med. 2019 Jun 04.
    View on PubMed
  2. Park JC, Ma TM, Rooper L, Hembrough T, Foss RD, Schmitt NC, Sawhney R, Flanders A, Kang H. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas. Head Neck. 2018 Dec; 40(12):E100-E106.
    View on PubMed
  3. Park JC, Gourin CG, Kiess AP, Mehra R, Forastiere AA, Kang H. Pattern of planned systemic therapy usage in newly diagnosed, nonmetastatic squamous cell carcinoma of the head and neck in a commercially insured population in the United States. Head Neck. 2018 Dec; 40(12):2612-2620.
    View on PubMed
  4. Kang H, Pettinga D, Schubert AD, Ladenson PW, Ball DW, Chung JH, Schrock AB, Madison R, Frampton GM, Stephens PJ, Ross JS, Miller VA, Ali SM. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy. Oncologist. 2018 Oct 29.
    View on PubMed
  5. Kwatra SG, Ständer S, Kang H. PD-1 Blockade-Induced Pruritus Treated with a Mu-Opioid Receptor Antagonist. N Engl J Med. 2018 Oct 18; 379(16):1578-1579.
    View on PubMed
  6. Karantanos T, Rooper L, Kang Y, Lin CT, Wenga P, Sagorsky S, Lauring J, Kang H. Clinical Benefit to an Aurora A Kinase Inhibitor in a Patient with Metastatic Integrase Interactor 1-Deficient Carcinoma. Oncologist. 2019 Feb; 24(2):146-150.
    View on PubMed
  7. Ho WJ, Yarchoan M, Hopkins A, Mehra R, Grossman S, Kang H. Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas. J Immunother Cancer. 2018 Aug 31; 6(1):84.
    View on PubMed
  8. Jung K, Park JC, Kang H, Brandes JC. Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer. Epidemiol Health. 2018; 40:e2018040.
    View on PubMed
  9. Rooper LM, Karantanos T, Ning Y, Bishop JA, Gordon SW, Kang H. Salivary Secretory Carcinoma With a Novel ETV6-MET Fusion: Expanding the Molecular Spectrum of a Recently Described Entity. Am J Surg Pathol. 2018 Aug; 42(8):1121-1126.
    View on PubMed
  10. Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018 Jul; 119(2):153-159.
    View on PubMed
  11. Kang H, Antonarakis ES, Luo J, Zheng Q, Rooper L, De Marzo AM, Westra WH, Lotan TL. Detection of AR-V7 transcript with RNA in situ hybridization in human salivary duct cancer. Oral Oncol. 2018 Sep; 84:134-136.
    View on PubMed
  12. Ho WJ, Rooper L, Sagorsky S, Kang H. A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer: a case report. J Immunother Cancer. 2018 May 09; 6(1):33.
    View on PubMed
  13. Motz K, Herbert RJ, Fakhry C, Quon H, Kang H, Kiess AP, Eisele DW, Koch WM, Frick KD, Gourin CG. Short- and long-term outcomes of oropharyngeal cancer care in the elderly. Laryngoscope. 2018 09; 128(9):2084-2093.
    View on PubMed
  14. Gourin CG, Herbert RJ, Fakhry C, Quon H, Kang H, Kiess AP, Koch WM, Eisele DW, Frick KD. Quality indicators of oropharyngeal cancer care in the elderly. Laryngoscope. 2018 10; 128(10):2312-2319.
    View on PubMed
  15. Gourin CG, Fakhry C, Quon H, Kang H, Kiess AP, Herbert RJ, Eisele DW, Frick KD. Treatment, survival, and costs of oropharyngeal cancer care in the elderly. Laryngoscope. 2018 05; 128(5):1103-1112.
    View on PubMed
  16. Schmitt NC, Kang H, Sharma A. Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy. Oral Oncol. 2017 11; 74:40-48.
    View on PubMed
  17. Guerrero-Preston R, White JR, Godoy-Vitorino F, Rodríguez-Hilario A, Navarro K, González H, Michailidi C, Jedlicka A, Canapp S, Bondy J, Dziedzic A, Mora-Lagos B, Rivera-Alvarez G, Ili-Gangas C, Brebi-Mieville P, Westra W, Koch W, Kang H, Marchionni L, Kim Y, Sidransky D. High-resolution microbiome profiling uncovers Fusobacterium nucleatum, Lactobacillus gasseri/johnsonii, and Lactobacillus vaginalis associated to oral and oropharyngeal cancer in saliva from HPV positive and HPV negative patients treated with surgery and chemo-radiation. Oncotarget. 2017 Dec 19; 8(67):110931-110948.
    View on PubMed
  18. Fung N, Faraji F, Kang H, Fakhry C. The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma. Cancer Metastasis Rev. 2017 09; 36(3):449-461.
    View on PubMed
  19. Britt CJ, Chang HY, Quon H, Kang H, Kiess AP, Eisele DW, Frick KD, Gourin CG. Quality indicators of laryngeal cancer care in commercially insured patients. Laryngoscope. 2017 12; 127(12):2805-2812.
    View on PubMed
  20. Day AT, Chang HY, Quon H, Kang H, Kiess AP, Eisele DW, Frick KD, Gourin CG. Treatment, short-term outcomes, and costs associated with larynx cancer care in commercially insured patients. Laryngoscope. 2018 01; 128(1):91-101.
    View on PubMed

Go to UCSF Profiles, powered by CTSI